Brokerages Set CryoPort, Inc. (NASDAQ:CYRX) PT at $11.00

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $11.00.

Several analysts have recently commented on the company. Roth Mkm restated a "buy" rating and set a $15.00 target price on shares of CryoPort in a report on Tuesday, April 1st. UBS Group raised their price objective on shares of CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th. Guggenheim restated a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a research report on Wednesday, April 16th. Finally, Morgan Stanley reduced their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th.

Insider Transactions at CryoPort

In other news, Director Robert J. Hariri sold 12,500 shares of CryoPort stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total transaction of $76,250.00. Following the transaction, the director now owns 8,061 shares in the company, valued at $49,172.10. The trade was a 60.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 151,304 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total value of $1,030,380.24. Following the sale, the chief executive officer now directly owns 912,419 shares of the company's stock, valued at approximately $6,213,573.39. The trade was a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 425,453 shares of company stock valued at $2,871,027 over the last three months. 10.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in CryoPort by 23.8% in the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after purchasing an additional 15,036 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of CryoPort by 106.4% in the first quarter. Acadian Asset Management LLC now owns 479,695 shares of the company's stock valued at $2,911,000 after purchasing an additional 247,288 shares in the last quarter. Needham Investment Management LLC boosted its position in shares of CryoPort by 13.7% during the first quarter. Needham Investment Management LLC now owns 277,500 shares of the company's stock worth $1,687,000 after buying an additional 33,500 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in shares of CryoPort by 54.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 113,235 shares of the company's stock worth $688,000 after buying an additional 39,698 shares during the period. Finally, Banque Transatlantique SA bought a new position in shares of CryoPort during the first quarter worth about $369,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Price Performance

NASDAQ:CYRX traded down $0.41 on Friday, reaching $6.37. The stock had a trading volume of 607,870 shares, compared to its average volume of 529,802. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $319.39 million, a P/E ratio of -2.72 and a beta of 1.85. CryoPort has a 1-year low of $4.58 and a 1-year high of $9.78. The stock has a fifty day moving average price of $6.20 and a 200-day moving average price of $6.70.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The business had revenue of $41.04 million for the quarter, compared to the consensus estimate of $56.19 million. Research analysts forecast that CryoPort will post -0.99 EPS for the current year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.